share_log

科兴控股:抗破伤风毒素单抗SNA02-48注射液获批临床默示许可

Sinovac Holdings: The monoclonal antibody SNA02-48 injection targeting tetanus toxin has been approved for clinical implied licensing.

Breakings ·  Mar 29 04:09

On March 27, Peking Sinovac Holdings (Group) Co., Ltd. (hereinafter referred to as 'Sinovac Holdings') announced that its subsidiary Beijing Sinovac Biotech Co., Ltd. collaborated with Xingmeng Biomedical (Suzhou) Co., Ltd. (hereinafter referred to as 'Xingmeng Biomedical') to jointly apply for the Class I new drug SNA02-48 injection, which has been approved for clinical implied licensing. This product is a recombinant fully human monoclonal antibody targeting tetanus toxin. In addition to the tetanus monoclonal antibody, Sinovac Holdings' application for the tetanus vaccine has been accepted in April 2024.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 390

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.